Targeted combo aims to shrink breast tumors before surgery

NCT ID NCT07054190

Recruiting now Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study tests whether combining the drug inavolisib with other treatments can safely shrink or eliminate early-stage breast tumors that have a specific genetic change (PIK3CA mutation). About 60 people with untreated stage II-III breast cancer will receive the drug combination before surgery. The main goals are to check safety and see how many patients have no cancer left at surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Asan Medical Center.
RECRUITING

Seoul, 05505, South Korea
Centre Hospitalier de l'Universite de Montreal (CHUM)
RECRUITING

Montreal, Quebec, H2X 0C2, Canada
Centro Médico Fleischer
RECRUITING

Buenos Aires, C1414DRK, Argentina
Centro Oncologico Korben
RECRUITING

Ciudad Autonoma Buenos Aires, C1426AGE, Argentina
Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda
RECRUITING

São Paulo, São Paulo, 01317-000, Brazil
Community Clinical Trials
RECRUITING

Orange, California, 92868, United States
Das Brustzentrum
RECRUITING

Berlin, 12623, Germany
HELIOS Klinikum Berlin-Buch
RECRUITING

Berlin, 13125, Germany
HELIOS Klinikum Schwerin
RECRUITING

Schwerin, 19055, Germany
Hospital Aleman de Buenos Aires
RECRUITING

Buenos Aires, C1118AAT, Argentina
Hospital Araujo Jorge
RECRUITING

Goiânia, Goiás, 74605-070, Brazil
Hospital Clinic Barcelona
RECRUITING

Barcelona, 08036, Spain
Hospital Clinico Universitario de Salamanca
RECRUITING

Salamanca, 37007, Spain
Hospital Clínico Universitario de Valencia
RECRUITING

Valencia, 46010, Spain
Hospital General Universitario Gregorio Marañon
RECRUITING

Madrid, 28007, Spain
Hospital Universitario 12 de Octubre
RECRUITING

Madrid, 28041, Spain
Hospital Universitario Virgen Macarena
RECRUITING

Seville, 41009, Spain
Hospital do Cancer de Pernambuco - HCP
RECRUITING

Recife, Pernambuco, 50040-000, Brazil
Irmandade Da Santa Casa de Misericordia de Porto Alegre
RECRUITING

Porto Alegre, Rio Grande do Sul, 90035-074, Brazil
Jewish General Hospital
RECRUITING

Montreal, Quebec, H3T1E2, Canada
Kliniken Essen-Mitte
RECRUITING

Essen, 45136, Germany
Los Angeles Cancer Network
RECRUITING

Los Angeles, California, 90017-4803, United States
McGill University Health Center
RECRUITING

Montreal, Quebec, H4A 3J1, Canada
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea
Severance Hospital, Yonsei University Health System
RECRUITING

Seoul, 03722, South Korea
St. Vincenz-Krankenhaus GmbH Paderborn Frauen- und Kinderklinik St. Louise
RECRUITING

Paderborn, 33098, Germany
Sunnybrook Odette Cancer Centre
RECRUITING

Toronto, Ontario, M4N 3M5, Canada
Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden
RECRUITING

Dresden, 01307, Germany
Universitätsklinikum Heidelberg
RECRUITING

Heidelberg, 69120, Germany
Vall d'Hebron Institute of Oncology (VHIO), Barcelona
RECRUITING

Barcelona, 08035, Spain
West Cancer Center
RECRUITING

Germantown, Tennessee, 38138, United States
West Virginia University
RECRUITING

Morgantown, West Virginia, 26506, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.